In a patient with moderate-to-severe chronic obstructive pulmonary disease, should the treatment regimen include budesonide 200 µg/glycopyrrolate 50 µg/formoterol 12 µg (Trelegy 200) twice daily, albuterol hydrofluoroalkane (albuterol HFA) as needed, and montelukast 10 mg, or are additional therapies needed?

Treatment Plan Assessment for Moderate-to-Severe COPD

Your current regimen of Trelegy 200, albuterol HFA PRN, and montelukast 10 mg is appropriate for moderate-to-severe COPD, but montelukast should be discontinued as it has no established role in COPD management. 1

Core Regimen Analysis

What You Have Right

Trelegy (budesonide/glycopyrrolate/formoterol) is the cornerstone therapy and represents optimal triple therapy (LAMA/LABA/ICS) for patients with moderate-to-severe COPD at high risk of exacerbations. 1 The 2023 Canadian Thoracic Society guidelines strongly support triple therapy as it:

• Reduces moderate/severe exacerbations by 24% compared to LAMA/LABA dual therapy
• Reduces severe exacerbations by 34% (rate ratio 0.66)
• Demonstrates mortality benefit with moderate-dose ICS (the 200 mcg budesonide formulation) 1

Albuterol HFA PRN is appropriate as rescue therapy for acute symptom relief. 2

What Needs to Change

Discontinue montelukast immediately. There is no evidence supporting leukotriene receptor antagonists in COPD management. 1, 3 While montelukast may provide benefit when added to budesonide/formoterol in patients with asthma 4, your question specifically addresses COPD, where this medication has no established role and represents unnecessary polypharmacy.

When to Add Additional Therapies

Do NOT add anything else unless the patient continues to exacerbate despite triple therapy. 1 The 2023 guidelines are explicit about this stepwise approach.

If Exacerbations Persist on Triple Therapy

Consider adding therapies only in this specific order based on patient phenotype:

1. Macrolide maintenance therapy (e.g., azithromycin 250 mg daily or 500 mg three times weekly)

• Required criteria: 1
  • Normal QT interval on ECG
  • No drug interactions with current medications
  • No evidence of atypical mycobacterial infection (obtain sputum AFB culture first)
• Strongest evidence for exacerbation reduction

2. For chronic bronchitic phenotype specifically:

• Roflumilast 500 mcg daily if FEV1 <50% predicted with chronic bronchitis and hospitalization for exacerbation in past year 1, 3
• N-acetylcysteine as alternative 1

Critical Pitfalls to Avoid

Do NOT step down from triple therapy in patients at high risk of exacerbations. Withdrawing ICS increases exacerbation risk, particularly if blood eosinophils ≥300 cells/μL. 1

Do NOT use:

• Theophylline (unfavorable harm-benefit profile) 1, 5
• Systemic oral corticosteroids for maintenance (prednisone) 1
• ICS monotherapy (no role in COPD) 1

Monitor for pneumonia risk with ICS-containing regimens, especially in severe/very severe disease. However, the number needed to harm is 33 patients for 1 year to cause one pneumonia, versus number needed to treat of 4 patients for 1 year to prevent one exacerbation—strongly favoring continued triple therapy. 1

Dosing Verification

Confirm you're using Trelegy once daily (not twice daily). The FDA-approved dosing is one inhalation daily. 2 The 200 mcg budesonide formulation specifically showed mortality benefit in the ETHOS trial. 1

Summary Algorithm

1. Continue Trelegy 200 once daily ✓
2. Continue albuterol HFA PRN ✓
3. Stop montelukast (no role in COPD)
4. Reassess in 3-6 months for exacerbation frequency
5. If ≥2 moderate or ≥1 severe exacerbation despite triple therapy → Add macrolide (after checking QT, drug interactions, AFB culture)
6. If chronic bronchitic phenotype with persistent exacerbations → Consider roflumilast or NAC